Lilly’s Alimta get favorable opinion for new use in Europe
If approved for continuation maintenance, Eli Lilly and Co.’s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
Eli Lilly and Co.
Articles
Debate rages over whether Lilly’s Byetta lifts cancer risk
A German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
Lilly invests $30M in chronic-disease partnerships
Drugmaker Eli Lilly and Co. said Tuesday it will spend $30 million over five years to fight chronic illnesses like heart disease, diabetes, cancer and respiratory disease in developing countries.
FDA gets new report on Lilly diabetes drug
Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
FDA deal with drugmakers raises user fees 6 percent
Drugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.
Lilly spent $1.9M lobbying feds in first quarter
Eli Lilly and Co. spent $1.9 million lobbying the federal government in the first quarter, focusing on the health care overhaul and overseas pricing reform, among many other issues.
Lilly wins appeals court ruling in Strattera patent case
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s patent on attention-deficit treatment Strattera was invalid.
Eli Lilly’s Elanco unit blossoming at just the right time
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
Despite sales spike, Effient has middling prospects
Remember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
Lilly stock rises after drugmaker reports higher sales
Investors responded favorably Thursday to Eli Lilly and Co.’s surprisingly strong second-quarter revenue, even though its profit fell due to rapid spending on marketing and research.
Pfizer won’t break up animal unit for potential Lilly bid
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
Lilly profit falls, but forecast rises after second quarter
Second-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
Lilly: Alzheimer’s patients on failed drug didn’t improve
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
FDA says potential diabetes drug may cause cancer
Dapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar drugs.
Lechleiter: German drug pricing creates ‘uncertainty’ for Lilly
Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy creates “uncertainty” for the company’s business planning.
Lilly’s Cialis finally overtakes Viagra
Why do drugmakers still pursue so many me-too drugs? Because, if marketed well, they can be extremely lucrative. Just ask Eli Lilly and Co. about its drug Cialis.
J&J completes sale of animal-drug business to Lilly
Janssen Pharmaceutica said Thursday it has completed the sale of its animal health business to Eli Lilly and Co. Inc.
Eli Lilly using big dividend to prevent investor exodus
Lilly executives are emphatic that they have no plans to reduce the company's 49-cents-a-share quarterly cash dividend, which gives the stock a rich annual yield of 5.2 percent.
Lilly loses bid to end revived Zyprexa U.K. patent case
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
R&D spending soars above value of new drugs
To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.